An update on iron chelation therapy

Blood Transfusion

Volumn 10, Issue 4, 2012, Pages 411-422

  Poggiali, Erika ^a   Cassinerio, Elena ^a   Zanaboni, Laura ^a   Cappellini, Maria Domenica ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chelation therapy; Iron; Iron overload; Thalassaemia; Transfusion dependent disorders

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FBS 0701; FERRITIN; IRON CHELATING AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTHRALGIA; BETA THALASSEMIA; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; BONE DISEASE; BONE MARROW DEPRESSION; CHELATION THERAPY; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRY WEIGHT; EAR DISEASE; ERYTHROCYTE COUNT; EYE DISEASE; FERRITIN BLOOD LEVEL; FULMINANT HEPATIC FAILURE; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS C; HUMAN; HYPERTRANSAMINASEMIA; IRON ABSORPTION; IRON BALANCE; IRON CHELATION; IRON CHELATION THERAPY; IRON INTAKE; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; LIFE EXPECTANCY; LIVER BIOPSY; LIVER FIBROSIS; LOCAL SKIN REACTION; LONG TERM CARE; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PROTEINURIA; PURE RED CELL ANEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DEVELOPMENT; SICKLE CELL ANEMIA; THALASSEMIA MAJOR; TRANSFUSION; VOMITING;

CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOCHROMATOSIS; HUMANS; IRON; MALE; THALASSEMIA;

EID: 84869991089     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0008-12     Document Type: Review

References (101)

1. Shander A, Cappellini MD, Goodnough L. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang 2009; 97: 185-97.
2. Kushner JP, Porter JB, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001; 47-61 http://asheducationbook. hematologylibrary.org/archive/index.dtl.
3. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-94. (Pubitemid 46753591)
4. Hershko C, Abrahamov A, Konijm AM, et al. Objectives and methods of iron chelation therapy. Bioinorg Chem Apl 2003; 1: 151-68.
5. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343: 327-31. (Pubitemid 30616698)
6. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Prat Res Clin Haematol 2005; 18: 277-87. (Pubitemid 40298370)
7. Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 2011; 90: 1-10.
8. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-93. (Pubitemid 39390442)
9. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-7.
10. Ardalan FA, Osquei MR, Toosi MN, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective crosssectional study. BMC Gastroenterol 2004; 4: 17.
11. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21. (Pubitemid 35177422)
12. Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011; 2011: 443-50.
13. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-20. (Pubitemid 35232104)
14. Wood JC. Cardiac iron across different transfusiondependent diseases. Blood Rev 2008; 22 (Suppl 2):S14-S21.
15. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-44.
16. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115: 2364-71.
17. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116: 537-43.
18. Kirk P, Roughton M, Porter JB, et al. Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-8.
19. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-73. (Pubitemid 24265698)
20. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104: 263-9. (Pubitemid 38879867)
21. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30: 698-705.
22. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous betathalassemia. N Engl J Med 1994; 331: 574-8. (Pubitemid 24265699)
23. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-61. (Pubitemid 27121266)
24. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-62.
25. Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984; 58: 369-73. (Pubitemid 14002111)
26. De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004; 2 (Suppl 2): 249-55.
27. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-36. (Pubitemid 30099831)
28. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2*cardiovascular magnetic resonance. Br J Haematol 2004; 127: 348-55. (Pubitemid 39468951)
29. Porter JB, Rafique R, Srichairatanakool S, et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann N Y Acad Sci 2005; 1054: 155-68. (Pubitemid 43031020)
30. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-602. (Pubitemid 36578996)
31. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47: 1919-29. (Pubitemid 47438560)
32. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamineor deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-7.
33. Abbruzzese G, Cossu G, Balocco M, et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011; 96: 1708-11.
34. Boddaert N, Le Quan Sang KH, Rötig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007; 110: 401-8. (Pubitemid 47026862)
35. Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008; 111: 1690-9. (Pubitemid 351213461)
36. Porter JB, Evangeli M, El-Beshlway A. The challenges of adherence and persistence with iron chelation therapy. Int J Hematol 2011; 94: 453-60.
37. Link G, Konijn AM, Breuer W, et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138: 130-8. (Pubitemid 32696277)
38. Evans P, Kayyali R, Hider RC, et al. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res 2010; 156: 55-67.
39. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583-7. (Pubitemid 37022545)
40. Henter JI, Karlén J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007; 109: 5157-9. (Pubitemid 46890530)
41. Addis A, Loebstein R, Koren G, Einarson TR. Metaanalytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 1999; 55: 1-6. (Pubitemid 29144092)
42. Taher A, Sheikh-Taha M, Sharara A, et al. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Acta Haematol 2005; 114: 146-9. (Pubitemid 41540337)
43. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-96. (Pubitemid 36648438)
44. Smith GC, Alpendurada F, Carpenter JP, et al. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson 2011; 13: 34.
45. Berdoukas V, Chouliaras G, Moraitis P, et al. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009; 11: 20.
46. Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr 2004; 41: 21-7. (Pubitemid 38139865)
47. Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91: 1241-3. (Pubitemid 44408435)
48. Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 2007; 92: 1599-606. (Pubitemid 350248238)
49. Daar S, Pathare AV. Combined theraphy with desferrioxamine and deferiprone in beta thalassemia major patients transfusional iron overload. An Hematol 2006; 85: 315-6.
50. El-Beshlaway A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol 2008; 87: 545-50.
51. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-84. (Pubitemid 46598901)
52. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10: 12.
53. Pantalone GR, Maggio A, Vitrano A, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients. Hemoglobin 2011; 35: 206-16.
54. Macklin, Investigational New Drug submission to the U.S. Food and Drug Administration, unpublished data, 2004.
55. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-80. (Pubitemid 44023139)
56. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565-72. (Pubitemid 36613115)
57. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80: 168-76.
58. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-8. (Pubitemid 46046309)
59. Cappellini MD. Efficacy and safety of deferasirox (exjade®) in pediatric patients with beta-thalassemia: update of 4.7-year efficacy and safety form extension studies [abstract]. Blood 2008; 112: ABS3883.
60. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557-66.
61. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009; 82: 458-65.
62. Deugneir Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011; 141: 1202-11, 1211.e1-3.
63. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2*over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011; 96: 48-54.
64. Lal L. Safety of combined chelation therapy with deferasirox and deferoxaminein transfusion-dependent thalassemia [Abstract]. Blood 2009; 114: 2021.
65. Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008; 120: 123-8.
66. Trad O, Hamdan MA, Jamil A, et al. Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia. Pediatr Blood Cancer 2009; 52: 426-8.
67. Berdoukas V, Farmaki K, Wood JC, Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol. 2011; 4: 17-26.
68. Porter JB. Deferoxamine pharmacokinetics. Semin Haematol 2001; 38 (1 Suppl 1): 63-8. (Pubitemid 32110273)
69. al-Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995; 89: 403-8.
70. Cabantchick ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-87. (Pubitemid 40298370)
71. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148: 466-75.
72. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a oncedaily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009; 82: 454-7.
73. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011; 118: 884-93.
74. Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008; 23: 320-3.
75. Gattermann N, Arisch A, Schlag R, et al. Deferasirox in iron-overloaded patients with transfusiondependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-50.
76. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in betathalassemia major. Blood 2008; 111: 583-7.
77. Porter JB, Lin KH, Beris P, et al. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol 2011; 87: 338-48.
78. Fox F. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only [abstract]. Blood 2009; 114 (22): ABS1747.
79. Leitch HA, Chase JM, Goodman TA, et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leukemia 2008; 2: 205-11.
80. Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010; 34: 864-70.
81. Sanz G. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood 2008; 112 (II): ABS640.
82. Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-50.
83. Oliva EN, Ronco F, Marino A, et al. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010; 50: 1568-70.
84. Breccia M, Loglisci G, Saiaroli A, et al. Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol 2010; 24: 46-8.
85. Gattermann N. Hematologic responses in myelodysplastic syndrome (MDS) patients treated with deferasirox: an EPIC post-hoc analysis using International Working Group (IWG) 2006 criteria [abstract]. Blood 2010; 116 (21): ABS2912.
86. Molteni A. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Haematologica 2010; 95 (Suppl 2): ABS640.
87. Syfuss PY, Ciupea A, Brahimi S, et al. Mild dehydrated hereditary stomatocytosis revealed by marked hepatosiderosis. Clin Lab Haematol 2006; 28: 270-4. (Pubitemid 44114642)
88. Kamble RT, Selby GB, Mims M, et al. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 506-10. (Pubitemid 43964819)
89. Mckay PJ, Murphy JA, Cameron S, et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 63-6. (Pubitemid 26031892)
90. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329: 840-4. (Pubitemid 23267211)
91. Kamble R, Mims M. Iron-overload in long-term survivors of hematopoietic transplantation. Bone Marrow Transplant 2006; 37: 805-6.
92. Butt NM, Clark RE. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. Bone Marrow Transplant 2003; 32: 909-13. (Pubitemid 37369269)
93. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006; 37: 857-64.
94. Morado M, Ojeda E, Garcia-Bustos J, et al. BMT: Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. Hematology 2000; 4: 505-12. (Pubitemid 30217860)
95. Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leukemia Res 2008; 32: 1338-53.
96. Pietrangelo A. Iron chelation beyond transfusion iron overload. Am J Hematol 2007; 82 (12 Suppl): 1142-6. (Pubitemid 350221246)
97. Gorman N, Zaharia A, Trask HS, et al. Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. Hepatology 2007; 46: 1927-34.
98. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649-57. (Pubitemid 47494365)
99. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011; 365: 576-8.
100. Rienhoff HY Jr, Viprakasit V, Tay L, et al. A phase I dose-escalation study: safety, tolerability, and pharmacokinetics of FBS070I, a novel iron chelator for the treatment of transfusional iron overload. Haematologica 2010; 96: 521-5.
101. Neufeld EJ, Galanello R, Viprakasit V, et al. A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood 2012; 119: 3263-8.